[go: up one dir, main page]

CN1706371A - A kind of efficient irinatin preparation and preparation method thereof - Google Patents

A kind of efficient irinatin preparation and preparation method thereof Download PDF

Info

Publication number
CN1706371A
CN1706371A CN 200510046524 CN200510046524A CN1706371A CN 1706371 A CN1706371 A CN 1706371A CN 200510046524 CN200510046524 CN 200510046524 CN 200510046524 A CN200510046524 A CN 200510046524A CN 1706371 A CN1706371 A CN 1706371A
Authority
CN
China
Prior art keywords
preparation
acid
oil
medicine
irisquinonum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN 200510046524
Other languages
Chinese (zh)
Other versions
CN1706371B (en
Inventor
邓意辉
吴红兵
徐速
吴琼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenyang Pharmaceutical University
Original Assignee
Shenyang Pharmaceutical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenyang Pharmaceutical University filed Critical Shenyang Pharmaceutical University
Priority to CN 200510046524 priority Critical patent/CN1706371B/en
Publication of CN1706371A publication Critical patent/CN1706371A/en
Application granted granted Critical
Publication of CN1706371B publication Critical patent/CN1706371B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Medicinal Preparation (AREA)

Abstract

The present invention is efficient sword-like iris seed preparation and its preparation process. The sword-like iris seed preparation may be liposome, emulsifier, nanometer particle or spray dried or freeze dried powder for orally taking or injection, and may have pharmaceutically acceptable preservative, sweetener and essence. The liposome consists of medicine, phospholipid and cholesterol in the weight ratio of 1 to 5-100 to 0-50, and has pH value of 4-8 and granularity of 5-5000 nm. The preparation process includes: 1. preparing oil phase in compounding tank, 2. preparing water phase in compounding tank, 3. adding water phase into oil phase to form initial emulsion, 4. suction filtering the initial emulsion in G3 funnel, regulating pH value to 3-9, and 5. processing in homogenizer, freeze drying and packing as emulsion. The preparation process of the present invention has fast and effective absorption and high blood medicine concentration.

Description

A kind of sword-like iris seed preparation and preparation method thereof efficiently
Technical field:
The present invention relates to medical technical field, exactly it is a kind of sword-like iris seed preparation and preparation method thereof efficiently.
Background technology:
The chemical name of Irisquinonum is: irisquinone, 6-methoxyl group-2-Δ 10 '-along 17 alkene-1,4-benzoquinone.But also contain the part dihydroirisquinone, pallason B.
Its structural formula is:
Figure A20051004652400041
Irisquinone
Molecular formula: C 24H 38O 3
Molecular weight: 374.56
Figure A20051004652400042
Dihydroirisquinone, pallason B
Molecular formula: C 24H 40O 3
Molecular weight: 376.58
The pharmacological action of Irisquinonum: be radiosensitizer, the growth of cell strain, tumor animal tumor and anoxic cells such as human cervical carcinoma, mice ehrlich ascites tumor, mouse lymphocyte leukemia is had radiosensitizing effect.Its mechanism of action is: suppress malignant cell and breathe, reduce oxygen consumption; Selectivity reduces malignant cell glutathion inside content; Suppress the synthetic and post-rift reparation of malignant cell DNA; Retardance malignant cell growth cycle is in to the ray sensitive G 1Phase.Acute toxicity: Irisquinonum is once irritated stomach LD 50Be 2590.6mg/kg; Mice once abdominal cavity injection LD 50Be 35.06 ± 0.99mg/kg.The animal poisoning symptom is hair pine, anorexia, loose stool, the visible flatulence of postmortem.Long term toxicity: 1. irritate stomach every day and give rat Irisquinonum 62.5,125,250mg/kg three months, the result shows liver function outer (SGPT slightly Irisquinonum raises), and hemogram and other main biochemical indicator do not have obvious change.2. irritate stomach every day and give Canis familiaris L. Irisquinonum 30mg/kg, 60mg/kg two months, the result shows that main organs do not see the substance damage that causes because of medicine.Main toxicity is gastrointestinal reaction, and this reaction prolongs or reduce dosage in time and recovery voluntarily.Tertogenicity test: the result shows continuous 10 days of the oral Irisquinonum 300mg/kg of pregnant Mus, can cause 25% animal dead, and can cause serious fetal toxicity reaction, makes most of pregnant Mus miscarry, absorb tire in early days, but tire Os Mus bone internal organs are not caused deformity; 60mg/kg treated animal filling stomach did not have obvious poisoning symptom in 10 days except that part animal perineum place secretions increase, symptom disappears automatically after the drug withdrawal, and skeleton of tire Mus and internal organs all do not cause deformity, show that Irisquinonum is non-teratogen.Mutagenicity test: microorganism reverse mutation test, sister chromatid exchange test, micronucleus test show that Irisquinonum is non-mutagen.Its plasma concentration is two chambers model, t after the oral this product of mice with tumor 1/2 αBe 0.096 hour, t 1/2 βBe 73.72 hours, Vd is 0.150L, shows that this product infiltration rate is fast, and the elimination time is long; The tissue distribution situation shows that medicine holdup time in digestive tract is long, and the tumor body radioactivity was the highest in 12 hours, and blood drug level still maintained this level in 24 hours, also has in lung and the thymus than high radioactivity, and brain and muscle are minimum.Behind this product single administration, existing than high radioactivity in the urine after half an hour, the discharge rate after 24 hours in excrement and the urine is respectively 14.8% and 30.3%.This product is a radiosensitizer, is used for the radiotherapy of radiocurable pulmonary carcinoma, esophageal carcinoma and incidence cancer etc.Oral meal, 2 times on the one, one time 2, take respectively at radiotherapy is forward and backward.Children's is cut down according to the circumstance.This product should begin to take before accepting radiotherapy 2-3 day, takes continuously until radiotherapy and finishes.Untoward reaction: part patient has slight gastrointestinal reaction, and as nausea,vomiting,diarrhea etc., its incidence rate height during than radiotherapy alone does not generally influence the continuation medication, reacts the patient individually, but decrement or symptomatic treatment, and one after each meal can reduce the reaction of stomach.Existing dosage form is capsule 55mg (in irisquinone and a dihydroirisquinone, pallason B total amount)
Irisquinonum is indissoluble in water, the while less stable, in order to improve dissolubility and stability in the water, there is the author to be made into cyclodextrin inclusion complex (the beta-schardinger dextrin-inclusion complex research Acta Pharmaceutica Sinica of cancer therapy drug Irisquinonum: 2002,37 (12): 963~966).In addition, because Irisquinonum indissoluble in water, its oral absorption is few (can be from irritating stomach LD 502590.6mg/kg; Mice once abdominal cavity injection LD 50Be 35.06 ± 0.99mg/kg, differ 70 surplus times) and individual variation big.For the injection feasibility is described, there is research worker to measure apparent pharmacokinetic parameters with chmice acute cumulative mortality method, the result shows that the apparent pharmacokinetic parameters of ip route of administration is similar to the gastric infusion approach, therefore taking drug administration by injection is feasible (the research Tianjin pharmacy 2002,14 (3) of the chmice acute cumulative mortality method mensuration apparent pharmacokinetic parameters of Irisquinonum: 36~37).
Irisquinonum is widely used (the Chinese clinical tumor of the perspective study of Irisquinonum radiation sensitization (attached 120 routine clinical analysis): 2003,30 (5): 328~330 in clinical; Irisquinonum is to anti-cisplatin Lu-csf-1 ADDP549 drug resistance inversion and possible machine-processed Chinese Medical Journal 2001,81 (22): 1392~1393; The clinical research Nanjing Medical University journal (natural science edition) 2001,21 (4): 328~330 of Irisquinonum sensitization in nasopharyngeal carcinoma radiotherapy; Treatment middle and advanced stage nasopharyngeal carcinoma efficacy analysis China clinical tumor 2001,28 (6): 439~440 is share in Irisquinonum and radiotherapy; Irisquinonum radiation sensitization treatment curative effect of esophageal carcinoma is observed Journal of Clinical Oncology: 2000,5 (4): 272~274; Irisquinonum influences Zhongshan Medical Univ.'s journal to 153SmEDTMP treatment nasopharyngeal carcinoma metastatic tumor of bone: 1998,19 (2): 142~143,149), and clinical effectiveness is remarkable, and effective percentage brings up to 62.5% by 10% during as therapeutic alliance; During the radiotherapy full dose, the tumor rate that disappears entirely brings up to 80% by 40%, and (the Irisquinonum capsule merges the Chinese clinical tumor of radiotherapy 62 routine esophageal carcinoma clinical observations: 1999,26 (8): 639~640), primary tumor and metastasis effective percentage, by 78.6%, 70.0% brings up to 94.3%, 87.5%, and (peace stuck glue capsule merges the Chinese clinical tumor 1999,26 (7) of radiotherapy malignant tumor 140 routine phase clinical observations: 547~548).
Blood albumin has important physiological function in blood, the normal osmotic pressure of blood is relevant with keeping, and is the main adjusting material of blood total osmotic pressure, lacks this albumin and may cause the body edema.Another effect of human albumin is to transport fatty acid as the carrier participation of fatty acid.Can utilize the human albumin as pharmaceutical carrier, the preparation nanometer formulation.
Summary of the invention:
But the objective of the invention is to prepare the preparation method of a kind of sword-like iris seed preparation efficiently and industrial applications thereof.Said efficient sword-like iris seed preparation comprises " liposome ", " Emulsion ", " nanoparticle ", and spray drying or lyophilized powder, prepared preparation can oral (antiseptic, sweeting agent, the essence that can add as required, the medicament allowed band) or drug administration by injection.Said antiseptic (antibacterial) is benzyl alcohol, benzoic acid (and salt), sorbic acid (and salt), parabens.Sweeting agent is sucrose, glucide, aspartame, protein sugar etc.; Essence is cream flavour, Fructus Citri tangerinae essence, cocoanut flavour, flavoring pineapple essence etc.Said lipid system is made up of medicine and phospholipid, cholesterol, and the ratio that medicine and phospholipid, cholesterol are formed is: 1: 5-100: 0-50 (W/W/W), its pH scope is: 4-8 (the medicine indissoluble is separated in this scope), particle size range is 10nm-5000nm.Said phospholipid is that PC (phosphatidylcholine) content is greater than 40% natural phospholipid, semi-synthetic phospholipid or synthetic phospholipid.Natural phospholipid comprises soybean lecithin, Ovum Gallus domesticus Flavus lecithin; Semi-synthetic phospholipid comprises hydrogenated soy phosphatidyl choline (HSPC), hydrogenated yolk lecithin; Synthetic phospholipid comprises DSPC (distearoyl phosphatidylcholine), DPPC (dipalmitoyl phosphatidyl choline), DMPC (dimyristoyl phosphatidyl choline), DLPC (two Laurel phosphatidyl cholines), DSPG (distearyl phosphatidyl glycerol), DPPG (two palmityl phosphatidyl glycerols), DMPG (GLYCEROL,DIMYRISTOYL PHOSPHATIDYL), DLPG (two lauroyl phosphatidyl glycerols), PA (phosphatidic acid), PI (phosphatidylinositols), PS (Phosphatidylserine).Said Emulsion is made up of medicine and oil phase, emulsifying agent, co-emulsifier, the proportion of composing of medicine and oil phase, emulsifying agent, co-emulsifier is: 1: 0.5-500: 1-50: 0-50 (W/W/W), its pH scope is: 4-8 (the medicine indissoluble is separated in this scope), particle size range is 10nm-5000nm.Said oil phase is C 0-C 18Vegetable oil or animal oil (comprising), triglyceride through the vegetable oil after structure of modification and the hydrolysis, as Oleum Cocois, olive oil, soybean oil, safflower oil, seal oil, hot certain herbaceous plants with big flowers acid glyceride (Delios ) (being called medium chain triglycerides MCT); The derivant that also comprises fatty acid is as ethyl oleate.Emulsifying agent comprises one or more mixture in phospholipid, HS15 (Polyethylene Glycol 12-hydroxy stearic acid ester, polyethylene glycol 660 hydroxystearate), vitamin E polyethylene glycol succinic acid ester (TPGS), the Tweens; Co-emulsifier comprises ethanol, glycerol, C 8-C 30Saturated or unsaturated fatty acid, as caproic acid, sad, certain herbaceous plants with big flowers is sour, one or more mixture in lauric acid, Palmic acid, (Asia) oleic acid, linoleic acid, stearic acid, docosahexenoic acid (DHA), cholic acid (pig, goose, ursodesoxycholic acid), dehydrocholic acid and the salt thereof; Said nanoparticle comprises " lipid nanoparticle " and " human albumin's (comprising human serum albumin (HSA), albumin human) nanoparticle ".Wherein " lipid nanoparticle " is made up of medicine and phospholipid substance, proportion of composing is: 1: whether 10-1000 (can change 1 into: 1-1000 embodiment 11) (W/W), also can add other appropriate ingredients as required, as vitamin E, HS15 (Polyethylene Glycol 12-hydroxy stearic acid ester, polyethylene glycol 660 hydroxystearate), vitamin E polyethylene glycol succinic acid ester (TPGS), DSPE-PEG, Poloxamer 407; Its pH scope is: 3-9, particle size range is 5nm-1000nm." human albumin's (comprising human serum albumin (HSA), albumin human) nanoparticle " is made up of medicine and human albumin, and wherein the ratio of Irisquinonum and human albumin, oil is 1: 1-100: 0-10, said oil are C 6-C 18Vegetable oil (comprising), triglyceride through the vegetable oil after structure of modification and the hydrolysis, as Oleum Cocois, olive oil, soybean oil, safflower oil, seal oil, hot certain herbaceous plants with big flowers acid glyceride (Delios ) (being called medium chain triglycerides MCT), its pH scope is: 3-9, particle size range is 5nm-1000nm.Said phospholipid substance comprises that PC (phosphatidylcholine) content forms greater than 40% albumin, and wherein the ratio of Irisquinonum and human albumin, oil is 1: 1~100: 0~10, and said oil is C 6~C 18Vegetable oil (comprising), triglyceride through the vegetable oil after structure of modification and the hydrolysis, as Oleum Cocois, olive oil, soybean oil, safflower oil, seal oil, hot certain herbaceous plants with big flowers acid glyceride (Delios ) (being called medium chain triglycerides MCT), its pH scope is: 3~9, and particle size range is 5nm~1000nm.Said phospholipid substance comprises that PC (phosphatidylcholine) content is greater than 40% natural phospholipid, semi-synthetic phospholipid or synthetic phospholipid.Natural phospholipid comprises soybean lecithin, Ovum Gallus domesticus Flavus lecithin; Semi-synthetic phospholipid comprises hydrogenated soy phosphatidyl choline, hydrogenated yolk lecithin; Synthetic phospholipid comprises DSPC (distearoyl phosphatidylcholine), DPPC (dipalmitoyl phosphatidyl choline), DMPC (dimyristoyl phosphatidyl choline), DLPC (two Laurel phosphatidyl cholines), DSPG (distearyl phosphatidyl glycerol), DPPG (two palmityl phosphatidyl glycerols), DMPG (GLYCEROL,DIMYRISTOYL PHOSPHATIDYL), DLPG (two lauroyl phosphatidyl glycerols), PA (phosphatidic acid), PI (phosphatidylinositols), PS (Phosphatidylserine).Can add antioxidant in the sword-like iris seed preparation of said injectable administration, comprise one or more mixture among Butylated hydroxyanisole (BHA), dibenzylatiooluene (BHT), alpha-tocopherol, α-tocopheryl acetate, alpha-lipoic acid, vitamin C, sodium L-ascorbate-2-phosphate, sulfurous acid (hydrogen) sodium, noble gas (nitrogen, argon), the EDTA (2Na or sodium calcium salt).The freeze drying protectant that said lyophilization injectable powder relates to is: one or more mixture in glucose, lactose, mannitol, sorbitol, xylitol, sucrose, trehalose, dextran, polyvinylpyrrolidone (PVP), glycine, succinylated gelatin, human albumin, the sodium chloride etc.; the content of freeze drying protectant is 2%~20% (W/V, protectant concentration in the preceding solution of lyophilizing).Described injection preparation method, with Emulsion is that example is described as follows: 1) prepare oil phase (medicine phase) in preparing tank: in preparing tank, oil for injection is heated to 20-90 ℃ when medicine (simple non-refuelling), adds emulsifying agent, strong agitation is to dissolving in the time of 20~80 ℃; Be cooled to 20~40 ℃ again, in stirring, add medicine.2) in preparing tank, prepare water: water and glycerol are stirred 5min down at 20~90 ℃, make it complete miscibility.3) in the time of 20~50 ℃, water is added in the oil phase, strong agitation 10~30min forms colostrum.4) colostrum is crossed G 3The funnel sucking filtration is regulated pH value to 4~8.5) cross the homogenizing instrument, the first step is regulated homogenize pressure to 520~600kg/cm 2, second step re-adjustment to 100~140kg/cm 2(or the microjet instrument, the first step is regulated homogenize pressure to 4000-8000psi, and the second step re-adjustment is to 10000-16000psi), form Emulsion.Cross the following microporous filter membrane of 0.8um or 0.8um, packing (add protective agent, carry out lyophilization, or carry out spray drying) promptly gets Emulsion.
Advantage of the present invention is: the mice in vivo test is the result show, prepared preparation infiltration rate of the present invention and degree are better than the commercial preparation far away, blood drug level is higher than the commercial preparation (nanoparticle of the Emulsion of the liposome of embodiment 2, embodiment 7, embodiment 14, its with respect to the bioavailability of commercial preparation all greater than 200%), the time of keeping also is longer than the commercial preparation.The curative effect of anti-mice ehrlich ascites tumor also is better than the commercial preparation.
The specific embodiment:
Detailed component of the present invention is provided by the following example, but protection scope of the present invention not only is confined to this.
Particle size analyzer: use PSS.NICOMP in this experiment TM380 as the instrument of measuring particle diameter.
Microjet instrument (Microfluidic company, the U.S.), homogenizer etc.
HPLC analyzes: chromatographic column: ODS post; Mobile phase: methanol-water-acetonitrile-ether (65: 25: 20: 20); Detect wavelength: 270nm; Flow velocity: 1mL/ minute.50μl。
Embodiment 1 Irisquinonum liposome
Composition weight (gram)
Irisquinonum 1
Soybean lecithin 5
Ethanol is an amount of
Citrate buffer solution adds to 100
Preparation technology:
Take by weighing Irisquinonum, the soybean lecithin of recipe quantity, behind an amount of dissolve with ethanol, (0.01mol/L, pH4.0), 40 ℃ are stirred aquation down, cross homogenizer (or microjet) (first step adjusting homogenize pressure 520~600kg/cm to add citrate buffer solution 2, second step re-adjustment 100~140kg/cm 2Microjet instrument, the first step are regulated homogenize pressure to 4000-8000psi, and the second step re-adjustment is to 10000-16000psi) get the Irisquinonum liposome, its granularity is 15nm~550nm.The trehalose that gained liposome liquid can add 12% (W/V) carries out lyophilization, gets freeze-dried lipidosome.After the redissolution, its granularity is 10nm~710nm.The gained preparation can oral or injection.
Embodiment 2 Irisquinonum liposomees
Composition weight (gram)
Irisquinonum 1
Soybean lecithin 50
Ethanol is an amount of
Alpha-tocopherol 0.1
Phosphate buffer adds to 1000
Preparation technology:
Take by weighing Irisquinonum, soybean lecithin, the alpha-tocopherol of recipe quantity, behind an amount of dissolve with ethanol, (0.01mol/L, pH5.0), 40 ℃ are stirred aquation down, cross homogenizer (or microjet), first step adjusting homogenize pressure 520kg/cm to add phosphate buffer 2, the second step re-adjustment 100kg/cm 2(or the microjet instrument, the first step is regulated homogenize pressure to 4000psi, and the second step re-adjustment is to 10000psi), get the Irisquinonum liposome, cross the 0.22um microporous filter membrane, its granularity is 25nm~430nm, envelop rate is greater than 90%.The glucose that gained liposome liquid can add the mannitol and 1% (W/V) of 6% (W/V) carries out lyophilization, gets freeze-dried lipidosome, every 5mg Irisquinonum (or vacuum gland).After the redissolution, its granularity is 20nm~710nm.The gained preparation can be oral (can add 0.1% sodium benzoate) or injection.
Embodiment 3 Irisquinonum liposomees
Composition weight (gram)
Irisquinonum 1
Ovum Gallus domesticus Flavus lecithin 20
Cholesterol 1
Alpha-lipoic acid 0.5
Ethanol is an amount of
Acetate buffer adds to 1000
Preparation technology:
Take by weighing Irisquinonum, Ovum Gallus domesticus Flavus lecithin, cholesterol, the alpha-lipoic acid of recipe quantity, behind an amount of dissolve with ethanol, adopt alcohol injection to add phosphate buffer (0.03mol/L, pH6.0) in, 50 ℃ are stirred aquation down, cross homogenizer (or microjet), the first step is regulated homogenize pressure to 600kg/cm 2, the second step re-adjustment is to 100kg/cm 2(or the microjet instrument, the first step is regulated homogenize pressure to 5000psi, and the second step re-adjustment is to 10000psi), getting the Irisquinonum liposome, its granularity is 10nm~820nm, crosses the 0.22um microporous filter membrane, envelop rate is greater than 90%.The lactose that gained liposome liquid can add the sucrose, 5% (W/V) of 10% (W/V) carries out lyophilization, promptly gets freeze-dried lipidosome; Or carry out spray drying, get pro-liposome.The packing inflated with nitrogen gets Liposomal formulation, every 5mg Irisquinonum (or vacuum gland).After the redissolution, its granularity is 20nm~780nm.The gained preparation can be oral (can add 0.1% sodium benzoate, 0.05% ethyl hydroxybenzoate) or injection.
Embodiment 4 Irisquinonum liposomees
Composition weight (gram)
Irisquinonum 1
DSPG 100
Cholesterol 50
Sodium L-ascorbate-2-phosphate 0.2
Ethanol is an amount of
Phosphate buffer adds to 5000
Preparation technology:
Take by weighing Irisquinonum, DSPG, the cholesterol sodium L-ascorbate-2-phosphate of recipe quantity, behind an amount of dissolve with ethanol, adopt alcohol injection to add phosphate buffer (0.03mol/L, pH7.0) in, 50 ℃ are stirred aquation down, cross homogenizer (or microjet), the first step is regulated homogenize pressure to 600kg/cm 2, the second step re-adjustment 140kg/cm 2(or the microjet instrument, the first step is regulated homogenize pressure to 8000psi, and the second step re-adjustment is to 16000psi), get the Irisquinonum liposome, cross the 0.3um microporous filter membrane, its granularity is 20nm~900nm, envelop rate is greater than 80%.The sucrose that gained liposome liquid can add 20% (W/V) carries out lyophilization, promptly gets freeze-dried lipidosome; Or carry out spray drying, get pro-liposome.The packing inflated with nitrogen gets Liposomal formulation, every 10mg Irisquinonum (or vacuum gland).After the redissolution, its granularity is 20nm~800nm.The gained preparation can oral or injection.
Embodiment 5 Irisquinonum liposomees
Composition weight (gram)
Irisquinonum 1
HSPC 10
DMPC 20
Ethanol is an amount of
Water for injection adds to 1000ml
Preparation technology:
Take by weighing Irisquinonum, HSPC, the DMPC of recipe quantity, behind an amount of dissolve with ethanol, add injection 600ml, in the gnotobasis, 50 ℃ are stirred aquation down, get the Irisquinonum liposome, and its granularity is 362nm~5000nm, and envelop rate is greater than 90%.The packing inflated with nitrogen gets Liposomal formulation, and every 5mg contains Irisquinonum (or vacuum gland).
Embodiment 6 Irisquinonum Emulsions
Composition weight (gram)
Irisquinonum 1
Soybean oil 0.5
Phosphatidase 11 0
Oleic acid 0.05
Glycerol 2.4
Water for injection adds to 200ml
Preparation technology:
1) prepare oil phase (medicine phase) in preparing tank: in preparing tank, add (injection) soybean oil, oleic acid (20 ℃), add emulsifying agent phospholipid, strong agitation is to dissolving in the time of 50 ℃; Be cooled to 40 ℃ again, in stirring, add medicine.2) in preparing tank, prepare water: water and glycerol are stirred 5min down at 90 ℃, make it complete miscibility.3) in the time of 50 ℃, water is added in the oil phase, strong agitation 30min forms colostrum.4) colostrum is crossed G 3The funnel sucking filtration.5) cross the homogenizing instrument, the first step is regulated homogenize pressure to 520kg/cm 2, the second step re-adjustment 140kg/cm 2(or the microjet instrument, the first step is regulated homogenize pressure 4000psi, and the second step re-adjustment is to 10000psi), form Emulsion, regulate pH value to 4.Cross the 0.3um microporous filter membrane, packing, inflated with nitrogen, every 1ml (containing medicine 5mg), every 2ml (containing medicine 10mg) or every 10ml (containing medicine 50mg), sterilization promptly gets (injection) Emulsion.Granularity is 10nm~1000nm, particle mean size 152nm.Add 20% (W/V) lactose, carry out lyophilization after the dissolving, promptly get freeze-dried emulsion; Or carry out spray drying, get precursor Emulsion.The packing inflated with nitrogen, every 5mg Irisquinonum.The gained preparation can oral or injection.
Embodiment 7 Irisquinonum Emulsions
Composition weight (kilogram)
Irisquinonum 1
Hot certain herbaceous plants with big flowers acid glyceride 20
HS15 2
Phosphatidase 11 0
Glycerol 12
Water for injection adds to 1000
Preparation technology:
1) prepare oil phase (medicine phase) in preparing tank: in preparing tank, add (injection or oral level) hot certain herbaceous plants with big flowers acid glyceride (50 ℃), add emulsifying agent phospholipid, HS15, strong agitation is to dissolving in the time of 80 ℃; Lower the temperature 30 ℃ again, in stirring, add medicine.2) in preparing tank, prepare water: water and glycerol are stirred 5min down at 90 ℃, make it complete miscibility.3) in the time of 40 ℃, water is added in the oil phase, strong agitation 30min forms colostrum.4) colostrum is crossed G 3The funnel sucking filtration is regulated pH value to 6.5) cross the homogenizing instrument, the first step is regulated homogenize pressure to 450kg/cm 2, the second step re-adjustment is to 120kg/cm 2(or the microjet instrument, the first step is regulated homogenize pressure to 6000psi, the second step re-adjustment 12000psi), form Emulsion.Cross the 0.3um microporous filter membrane, packing, inflated with nitrogen, every 3ml (containing medicine 3mg) or every 6ml (containing medicine 6mg), sterilization promptly gets injectable emulsion.Granularity is 50nm~700nm, particle mean size 178nm.The sucrose that can add 20% (W/V) in the gained Emulsion carries out lyophilization, promptly gets freeze-dried emulsion; Or carry out spray drying, get precursor Emulsion.The packing inflated with nitrogen, every 5mg Irisquinonum.After the redissolution, its granularity is 65nm~960nm.The gained preparation can be oral (can add 0.1% sodium benzoate, 0.05% ethyl hydroxybenzoate, cream flavour) or injection.
Embodiment 8 Irisquinonum Emulsions
Composition weight (gram)
Irisquinonum 1
Oleum Cocois 10
TPGS 10
Glycerol 12
Alpha-tocopherol 1
Water for injection adds to 1000
Preparation technology:
Operation is with embodiment 7, and granularity is 20nm~750nm, particle mean size 89nm.Every 5ml (containing medicine 5mg) or every 10ml (containing medicine 10mg) (applying argon gas).Mannitol, 2% xylitol that can add 8% (W/V) in the gained Emulsion carry out lyophilization, promptly get freeze-dried emulsion; Or carry out spray drying, get precursor Emulsion.The packing inflated with nitrogen, every 5mg Irisquinonum.After the redissolution, its granularity is 15nm~680nm.The gained preparation can oral (0.1% ethyl hydroxybenzoate, 0.05% propylparaben, protein sugar, cocoanut flavour) or injection.
Embodiment 9 Irisquinonum Emulsions
Composition weight (gram)
Irisquinonum 0.1
Hot certain herbaceous plants with big flowers acid glyceride 50
Soybean oil 0.5
TPGS 10
Poloxamer?407 5
Glycerol 2.4
Alpha-lipoic acid 1
Water for injection adds to 200
Preparation technology:
Operation is with embodiment 7, and granularity is 50nm~1060nm.Every 10ml (containing medicine 5mg) (argon).The gained preparation can oral or injection.
Embodiment 10 Irisquinonum Emulsions
Composition weight (kilogram)
Irisquinonum 1
Ethyl oleate 10
Phosphatidase 12
HS15 2
DHA 10
Glycerol 1.2
Alpha-lipoic acid 0.2
Water for injection adds to 200
Preparation technology:
Operation is with embodiment 7, pH8, and the sterile working, granularity is 100nm~5000nm.Every 1ml (containing medicine 5mg) or every 2ml (containing medicine 10mg), (applying argon gas).Add 6% mannitol, 6% xylitol, lyophilizing or spray drying get pressed powder.The gained preparation can oral or injection.
Embodiment 11 Irisquinonum nanoparticles
Composition weight (gram)
Irisquinonum 1
Soybean lecithin 10
HS15 5
Ethanol is an amount of
Alpha-lipoic acid 1
Glycerol 2
Water adds to 1000
Preparation technology:
Take by weighing Irisquinonum, phospholipid, HS15, the alpha-lipoic acid of recipe quantity, place material-compound tank, add ethanol, after 50 ℃ of heating for dissolving, add entry (containing glycerol) and stir, disperse, transfer pH to 4, cross homogenizer (or microjet), the first step is regulated homogenize pressure to 600kg/cm 2, the second step re-adjustment is to 140kg/cm 2(or the microjet instrument, the first step is regulated homogenize pressure to 8000psi, and the second step re-adjustment is to 16000psi), get the Irisquinonum liquid nano, cross 0.22 μ m microporous filter membrane degerming, packing, every 10ml (containing medicine 10mg) (applying argon gas).The mensuration granularity is 5nm~500nm.Add 10% sucrose in the gained liquid, carry out spray drying or lyophilization, get sterilized powder.Granularity after spray drying or the lyophilization gained solid rehydration is: 10nm~1000nm.The gained preparation can oral or injection.
Embodiment 12 Irisquinonum nanoparticles
Composition weight (gram)
Irisquinonum 0.1
Ovum Gallus domesticus Flavus lecithin 100
Hydrogenated soy phosphatidyl choline 1
Ethanol is an amount of
Vitamin E 1
Glycerol 30
Mannitol 50
Water adds to 1000
Preparation technology:
Take by weighing Irisquinonum, phospholipid, vitamin E, the hydrogenated soy phosphatidyl choline of recipe quantity, place material-compound tank, add ethanol, after 60 ℃ of heating for dissolving, standby.Take by weighing mannitol, the glycerol of recipe quantity in addition, behind the adding water dissolution, mix with above-mentioned Irisquinonum phospholipid solution, stir aquation, transfer pH to 6, cross homogenizer (or microjet), the first step is regulated homogenize pressure to 500kg/cm 2, the second step re-adjustment is to 120kg/cm 2(or the microjet instrument, the first step is regulated homogenize pressure to 6000psi, and the second step re-adjustment is to 13000psi), get the Irisquinonum liquid nano.Its granularity is 5nm~300nm.Cross 0.22 μ m microporous filter membrane degerming, packing, inflated with nitrogen.Gained liquid carries out spray drying or lyophilization, gets sterilized powder.Granularity after the rehydration is: 10nm~400nm.The gained preparation can oral or injection.
Embodiment 13 Irisquinonum nanoparticles
Composition weight (gram)
Irisquinonum 0.1
The human albumin 3
Dichloromethane is an amount of
Preparation technology:
Take by weighing the Irisquinonum of recipe quantity,, make the solution of 100mg/ml with the dichloromethane dissolving, standby.Get commercially available human albumin (25%) and be diluted to 5% solution, and be 5.5 with hydrochloric acid adjusting pH value with water for injection, standby.Under 0 ℃ the Irisquinonum dichloromethane solution is mixed with human albumin's solution, cross homogenizer (or microjet), the first step is regulated homogenize pressure to 600kg/cm 2, the second step re-adjustment is to 140kg/cm 2(or the microjet instrument, the first step is regulated homogenize pressure to 6000psi, and the second step re-adjustment is to 36000psi), get the Irisquinonum liquid nano.Its granularity is 5nm~550nm.Cross 0.22 μ m microporous filter membrane degerming, packing, lyophilization gets sterilized powder.Particle mean size after the rehydration (normal saline or sterilized water for injection) is: 170nm.Can be with different ratios, different acid replaces hydrochloric acid as citric acid, phosphoric acid, tartaric acid, acetic acid, and pH value is 3~8, can obtain similar results.The gained preparation can oral or injection.
Embodiment 14 Irisquinonum nanoparticles
Composition weight (gram)
Irisquinonum 1
Ovum Gallus domesticus Flavus lecithin 30
Ethanol is an amount of
Vitamin E 1
Deoxycholic acid 10
Mannitol 50
Glucose 10
Water adds to 1000
Preparation technology:
Take by weighing Irisquinonum, phospholipid, vitamin E, the deoxycholic acid of recipe quantity, place material-compound tank, add ethanol, after 50 ℃ of heating for dissolving, standby.Take by weighing mannitol, the glucose of recipe quantity in addition, behind the adding water dissolution, mix with above-mentioned Irisquinonum phospholipid solution, stir aquation, transfer pH to 8, cross homogenizer (or microjet), the first step is regulated homogenize pressure to 600kg/cm 2, the second step re-adjustment is to 140kg/cm 2(or the microjet instrument, the first step is regulated homogenize pressure to 7000psi, and the second step re-adjustment is to 26000psi), get the Irisquinonum liquid nano.Its granularity is 5nm~500nm.Cross 0.22 μ m microporous filter membrane degerming, packing, every 5ml (contains medicine (inflated with nitrogen).Gained liquid carries out spray drying or lyophilization, gets sterilized powder.Granularity after the rehydration is: 10nm~500nm.The gained preparation can oral or injection.

Claims (10)

1、一种高效的马蔺子素制剂,其特征在于:将马蔺子素制剂制成“脂质体”、“乳剂”、“纳米粒”,及其喷雾干燥或冷冻干燥粉,制剂中可以加入药剂允许范围的防腐剂、甜味剂、香精,所制备的制剂可以口服或注射给药。1, a kind of efficient irinatin preparation, it is characterized in that: irinatin preparation is made into " liposome ", " emulsion ", " nanoparticle ", and spray-dried or freeze-dried powder thereof, can add medicament to allow A wide range of preservatives, sweeteners, flavors, prepared preparations can be administered orally or by injection. 2、根据权利要求1中所说的一种高效的马蔺子素制剂,其特征在于:防腐剂或称抑菌剂为苯甲醇、苯甲酸或其盐、山梨酸或其盐、尼泊金酯类;甜味剂为蔗糖、糖精、阿斯巴甜、蛋白糖等;香精为奶油香精、橘子香精、椰子香精、菠萝香精。2. A kind of high-efficiency irinatin preparation according to claim 1, characterized in that: preservatives or antibacterial agents are benzyl alcohol, benzoic acid or its salts, sorbic acid or its salts, paraben esters ; Sweeteners are sucrose, saccharin, aspartame, protein sugar, etc.; flavors are cream flavor, orange flavor, coconut flavor, pineapple flavor. 3、根据权利要求1中所说的一种高效的马蔺子素制剂,其特征在于:所说的脂质体系由药物与磷脂、胆固醇组成,药物与磷脂、胆固醇组成的比例为:1∶5~100∶0~50(W/W/W),其pH范围为:4~8,粒度范围为5nm~5000nm,脂质体制备方法为乙醇注入法,或乙醇溶解分散法。3. A kind of high-efficiency echinacea preparation according to claim 1, characterized in that: said lipid system is composed of medicine, phospholipid and cholesterol, and the ratio of medicine, phospholipid and cholesterol is: 1:5~ 100: 0-50 (W/W/W), the pH range is 4-8, the particle size range is 5nm-5000nm, the liposome preparation method is ethanol injection method, or ethanol dissolution and dispersion method. 4、根据权利要求3中所说的一种高效的马蔺子素制剂,其特征在于:所说的磷脂为PC或称磷脂酰胆碱含量大于40%的天然磷脂、半合成磷脂或合成磷脂,天然磷脂包括大豆卵磷脂、蛋黄卵磷脂;半合成磷脂包括氢化大豆卵磷脂HSPC、氢化蛋黄卵磷脂;合成磷脂包括DSPC二硬脂酰磷脂酰胆碱、DPPC二棕榈酰磷脂酰胆碱、DMPC二肉豆蔻酰磷脂酰胆碱、DLPC二月桂酰磷脂酰胆碱、DSPG二硬脂酰磷脂酰甘油、DPPG二棕榈酰磷脂酰甘油、DMPG二肉豆蔻酰磷脂酰甘油、DLPG二月桂酰磷脂酰甘油、PA磷脂酸、PI磷脂酰肌醇、PS磷脂酰丝氨酸。4. A kind of high-efficiency irinatin preparation according to claim 3, characterized in that: said phospholipid is PC or natural phospholipid, semi-synthetic phospholipid or synthetic phospholipid with phosphatidylcholine content greater than 40%, natural Phospholipids include soybean lecithin, egg yolk lecithin; semi-synthetic phospholipids include hydrogenated soybean lecithin HSPC, hydrogenated egg yolk lecithin; synthetic phospholipids include DSPC distearoylphosphatidylcholine, DPPC dipalmitoylphosphatidylcholine, DMPC dimeat Myristoylphosphatidylcholine, DLPC dilauroylphosphatidylcholine, DSPG distearoylphosphatidylglycerol, DPPG dipalmitoylphosphatidylglycerol, DMPG dimyristoylphosphatidylglycerol, DLPG dilauroylphosphatidylglycerol, PA phosphatidic acid, PI phosphatidylinositol, PS phosphatidylserine. 5、根据权利要求1中所说的一种高效的马蔺子素制剂,其特征在于:所说的乳剂由药物与油相、乳化剂、助乳化剂组成,药物与油相、乳化剂、助乳化剂的组成比例为:1∶0.5~500∶1~50∶0~50(W/W/W),其pH范围为:4~8,粒度范围为10nm~5000nm。5, according to said a kind of high-efficiency irinacid preparation in claim 1, it is characterized in that: said emulsion is made up of medicine and oil phase, emulsifier, co-emulsifier, medicine and oil phase, emulsifier, co-emulsifier The composition ratio of the agent is: 1:0.5-500:1-50:0-50 (W/W/W), the pH range is 4-8, and the particle size range is 10nm-5000nm. 6、根据权利要求1中所说的一种高效的马蔺子素制剂,其特征在于:所说的油相为C6~C18的植物油或动物油、甘油三酸酯,椰子油、橄榄油、大豆油、红花油、海豹油、辛葵酸甘油酯或称为中链三甘油酯MCT;也包括脂肪酸的衍生物,如油酸乙酯。乳化剂包括磷脂、HS15TPGS、DSPE-PEG、Poloxamer 407、吐温类中的一种或几种混合物;助乳化剂包括乙醇、甘油、C6~C30的饱和或不饱和脂肪酸,如己酸、辛酸、葵酸、月桂酸、棕榈酸、油酸或亚油酸、亚麻油酸、硬脂酸、二十二碳六烯酸DHA、胆酸、去氧胆酸、去氢胆酸及其盐中的一种或几种混合物;6. A kind of high-efficiency irinatin preparation according to claim 1, characterized in that: said oily phase is vegetable oil or animal oil of C6C18 , triglyceride, coconut oil, olive oil, Soybean oil, safflower oil, seal oil, glyceryl caprylate or known as medium-chain triglycerides MCT; also includes derivatives of fatty acids such as ethyl oleate. Emulsifiers include one or more mixtures of phospholipids, HS15TPGS, DSPE-PEG, Poloxamer 407, and Tweens; co-emulsifiers include ethanol, glycerin, C 6 ~ C 30 saturated or unsaturated fatty acids, such as caproic acid, Caprylic acid, capric acid, lauric acid, palmitic acid, oleic acid or linoleic acid, linoleic acid, stearic acid, docosahexaenoic acid DHA, cholic acid, deoxycholic acid, dehydrocholic acid and their salts One or a mixture of several of them; 7、根据权利要求1中所说的一种高效的马蔺子素制剂,其特征在于:所说的纳米粒包括“脂质纳米粒”和“人血白蛋白纳米粒”;其中“脂质纳米粒”由药物与磷脂类物质组成,组成比例为:1∶1~1000(W/W),也可根据需要加入维生素E、HS15即聚乙二醇12-羟基硬脂酸酯、维生素E聚乙二醇琥珀酸酯即TPGS、DSPE-PEG、Poloxamer 407;其pH范围为:3~9,粒度范围为5nm~1000nm;“人血白蛋白纳米粒”由药物与人血白蛋白组成,其中马蔺子素与人血白蛋白、油的比例为1∶1~100∶0~10,所说的油为C6~C18的植物油、甘油三酸酯,如椰子油、橄榄油、大豆油、红花油、海豹油、辛葵酸甘油酯或称为中链三甘油酯MCT,其pH范围为:3~9,粒度范围为5nm~1000nm。7. According to claim 1, said a kind of high-efficiency echinacin preparation is characterized in that: said nanoparticles include "lipid nanoparticles" and "human albumin nanoparticles"; wherein "lipid nanoparticles "It is composed of drugs and phospholipids, and the composition ratio is: 1:1~1000 (W/W). Vitamin E, HS15 (polyethylene glycol 12-hydroxystearate, vitamin E polyethylene glycol) can also be added as needed. Diol succinate is TPGS, DSPE-PEG, Poloxamer 407; its pH range is: 3-9, and the particle size range is 5nm-1000nm; "Human albumin nanoparticles" are composed of drugs and human albumin, of which horse The ratio of Linzisu to human serum albumin and oil is 1:1~100:0~10, and the said oil is C 6 ~C 18 vegetable oil and triglyceride, such as coconut oil, olive oil, soybean oil, red Flower oil, seal oil, caprylic acid glyceride or medium-chain triglyceride MCT, its pH range is 3-9, and the particle size range is 5nm-1000nm. 8、根据权利要求7中所说的一种高效的马蔺子素制剂,其特征在于:所说的磷脂类物质包括磷脂酰胆碱,含量大于40%的天然磷脂、半合成磷脂或合成磷脂;天然磷脂包括大豆卵磷脂、蛋黄卵磷脂;半合成磷脂包括氢化大豆卵磷脂、氢化蛋黄卵磷脂;合成磷脂包括DSPC二硬脂酰磷脂酰胆碱、DPPC二棕榈酰磷脂酰胆碱、DMPC二肉豆蔻酰磷脂酰胆碱、DLPC二月桂酰磷脂酰胆碱、DSPG二硬脂酰磷脂酰甘油、DPPG二棕榈酰磷脂酰甘油、DMPG二肉豆蔻酰磷脂酰甘油、DLPG二月桂酰磷脂酰甘油、PA磷脂酸、PI磷脂酰肌醇、PS磷脂酰丝氨酸。8. According to a kind of high-efficiency irinatin preparation according to claim 7, it is characterized in that: said phospholipids include phosphatidylcholine, natural phospholipids, semi-synthetic phospholipids or synthetic phospholipids with a content greater than 40%; natural Phospholipids include soybean lecithin, egg yolk lecithin; semi-synthetic phospholipids include hydrogenated soybean lecithin, hydrogenated egg yolk lecithin; synthetic phospholipids include DSPC distearoylphosphatidylcholine, DPPC dipalmitoylphosphatidylcholine, DMPC dimyrist Acylphosphatidylcholine, DLPC dilauroylphosphatidylcholine, DSPG distearoylphosphatidylglycerol, DPPG dipalmitoylphosphatidylglycerol, DMPG dimyristoylphosphatidylglycerol, DLPG dilauroylphosphatidylglycerol, PA Phosphatidic acid, PI phosphatidylinositol, PS phosphatidylserine. 9、根据权利要求1中所说的一种高效的马蔺子素制剂,其特征在于:所说的马蔺子素制剂中可加入抗氧化剂,包括丁基羟基茴香醚BHA、二丁基羟基甲苯BHT、α-生育酚、α-醋酸生育酚、α-硫辛酸、维生素C、维生素C棕榈酸酯、亚硫酸钠或亚硫酸氢钠、惰性气体、EDTA 2Na、或钠钙盐中的一种或几种混合物;所说的喷雾干燥或冷冻干燥粉针剂涉及的冻干保护剂为:葡萄糖、乳糖、甘露醇、山梨醇、木糖醇、蔗糖、海藻糖、右旋糖苷、聚乙烯吡咯烷酮(PVP)、甘氨酸、琥珀明胶、人血白蛋白、氯化钠中的一种或几种混合物,冻干保护剂的含量为2%~20%(W/V),冻干前溶液中保护剂的浓度。9. A high-efficiency irinazoline preparation according to claim 1, characterized in that: antioxidants can be added to said irinazoline preparation, including butyl hydroxyanisole BHA, dibutyl hydroxytoluene BHT, α - One or more mixtures of tocopherol, α-tocopheryl acetate, α-lipoic acid, vitamin C, vitamin C palmitate, sodium sulfite or sodium bisulfite, inert gas, EDTA 2Na, or sodium calcium salt; The lyoprotectant involved in said spray-drying or freeze-drying powder injection is: glucose, lactose, mannitol, sorbitol, xylitol, sucrose, trehalose, dextran, polyvinylpyrrolidone (PVP), glycine, One or more mixtures of succinic gelatin, human serum albumin and sodium chloride, the content of the freeze-drying protectant is 2% to 20% (W/V), and the concentration of the protectant in the solution before freeze-drying. 10、一种如权利要求1中所说的一种高效的马蔺子素制剂的制备方法,其特征在于:乳剂制备方法如下:1)在配制罐中制备油相既药物相,在配制罐中,将油加热至20-90℃单纯药物时不加油,加入乳化剂,20~80℃时强烈搅拌至溶解;再降温至20~40℃,在搅拌中加入药物,2)在配制罐中制备水相:将水和甘油在20~90℃下搅拌5min,使之完全混溶,3)在20~50℃时,将水相加入油相中,强烈搅拌10~30min,形成初乳;4)将初乳过G3漏斗抽滤,调节pH值到3~9,5)过均质仪,第一步调节匀化压力至520~600kg/cm2,第二步再调节至100~140kg/cm2或过微射流仪,第一步调节匀化压力至4000-8000psi,第二步再调节至10000-16000psi,形成乳剂;过0.8um或0.8um以下的微孔滤膜,加入保护剂,进行冷冻干燥,或进行喷雾干燥,分装,即得乳剂。10, a kind of preparation method of a kind of efficient echinacea preparation as said in claim 1, it is characterized in that: emulsion preparation method is as follows: 1) prepare oily phase and medicine phase in preparation tank, in preparation tank, Heat the oil to 20-90°C and add the emulsifier without oil when the medicine is pure, and stir vigorously until it dissolves at 20-80°C; then cool down to 20-40°C, add the medicine while stirring, 2) prepare water in the preparation tank Phase: Stir water and glycerin at 20-90°C for 5 minutes to make them completely miscible. 3) Add the water phase to the oil phase at 20-50°C and stir vigorously for 10-30 minutes to form colostrum; 4) Filter the colostrum through a G3 funnel, adjust the pH value to 3~9, 5) pass through a homogenizer, adjust the homogenization pressure to 520~600kg/cm 2 in the first step, and then adjust it to 100~140kg/cm2 in the second step 2 or pass through a microfluidizer, adjust the homogenization pressure to 4000-8000psi in the first step, and then adjust to 10000-16000psi in the second step to form an emulsion; pass through a microporous membrane of 0.8um or less, add a protective agent, and carry out Freeze-drying or spray-drying, sub-packaging to obtain the emulsion.
CN 200510046524 2005-05-27 2005-05-27 Efficient sword-like iris seed preparation and its preparation process Expired - Fee Related CN1706371B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN 200510046524 CN1706371B (en) 2005-05-27 2005-05-27 Efficient sword-like iris seed preparation and its preparation process

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN 200510046524 CN1706371B (en) 2005-05-27 2005-05-27 Efficient sword-like iris seed preparation and its preparation process

Publications (2)

Publication Number Publication Date
CN1706371A true CN1706371A (en) 2005-12-14
CN1706371B CN1706371B (en) 2010-11-10

Family

ID=35580605

Family Applications (1)

Application Number Title Priority Date Filing Date
CN 200510046524 Expired - Fee Related CN1706371B (en) 2005-05-27 2005-05-27 Efficient sword-like iris seed preparation and its preparation process

Country Status (1)

Country Link
CN (1) CN1706371B (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102802605A (en) * 2009-04-30 2012-11-28 雅培制药有限公司 Stable lipid formulations of apoptosis promoters
CN103200932A (en) * 2010-06-23 2013-07-10 布莱特赛德创新有限公司 Lecithin carrier vesicles and methods of making the same
CN103800910A (en) * 2012-11-14 2014-05-21 沈阳药科大学 Composition capable of eliminating clouding phenomenon of Tween surfactants
US8927009B2 (en) 2009-12-22 2015-01-06 Abbvie Inc. ABT-263 capsule
US9642796B2 (en) 2009-06-08 2017-05-09 Abbvie Inc. Pharmaceutical dosage form for oral administration of a bcl 2 family inhibitor
CN113041222A (en) * 2021-03-23 2021-06-29 北京诺康达医药科技股份有限公司 Injection emulsion and preparation method thereof
US11369599B2 (en) 2010-10-29 2022-06-28 Abbvie Inc. Melt-extruded solid dispersions containing an apoptosis-inducing agent

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100377712C (en) * 2002-11-28 2008-04-02 沈阳药科大学 Cucurbitacin Liposome Prescription and Its Preparation

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102802605A (en) * 2009-04-30 2012-11-28 雅培制药有限公司 Stable lipid formulations of apoptosis promoters
US8728516B2 (en) 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
CN102802605B (en) * 2009-04-30 2015-08-12 Abbvie公司 Stable lipid formulations of apoptosis promoters
US9642796B2 (en) 2009-06-08 2017-05-09 Abbvie Inc. Pharmaceutical dosage form for oral administration of a bcl 2 family inhibitor
US8927009B2 (en) 2009-12-22 2015-01-06 Abbvie Inc. ABT-263 capsule
TWI508729B (en) * 2009-12-22 2015-11-21 Abbvie Inc Abt-263 capsule
CN103200932A (en) * 2010-06-23 2013-07-10 布莱特赛德创新有限公司 Lecithin carrier vesicles and methods of making the same
US11369599B2 (en) 2010-10-29 2022-06-28 Abbvie Inc. Melt-extruded solid dispersions containing an apoptosis-inducing agent
CN103800910A (en) * 2012-11-14 2014-05-21 沈阳药科大学 Composition capable of eliminating clouding phenomenon of Tween surfactants
CN103800910B (en) * 2012-11-14 2015-12-09 沈阳药科大学 The composition that can eliminate the phenomenon of Tween surfactants
CN113041222A (en) * 2021-03-23 2021-06-29 北京诺康达医药科技股份有限公司 Injection emulsion and preparation method thereof

Also Published As

Publication number Publication date
CN1706371B (en) 2010-11-10

Similar Documents

Publication Publication Date Title
EP2144610B1 (en) Melatonin tablet and methods of preparation and use
US6441050B1 (en) Palatable oral coenzyme Q liquid
CN1620283A (en) Preparation of dispersions of slightly or poorly soluble active ingredients
CN1042080A (en) Pharmaceutical carrier
JP3486778B2 (en) Alzheimer's disease preventive / treatment agent
CN1857222A (en) Submicron docetaxel emulsion for intravenous injection and its preparing process
AU2019363244B2 (en) Pharmaceutical formulation
JP2014133764A (en) Taxol submicroemulsion with steroidal compound as intermediate carrier
PT2345426E (en) Composite organic compound powder for medical use, method for producing same and suspension of same
CN1525850A (en) Coenzyme Q10 containing microemulsion preconcentrates and microemulsions
CN1596882A (en) Vitamin K1 emulsion and its freeze-dried emulsion and preparation method
WO2021196659A1 (en) Glycosyl polyether compound liposome, preparation method therefor and medicine thereof
CN1706371A (en) A kind of efficient irinatin preparation and preparation method thereof
WO2022061870A1 (en) Vitamin k2 microcapsule, preparation method therefor, and application thereof in preparation of medicine for preventing and treating cardiovascular and cerebrovascular diseases
CN102552134A (en) Fat emulsion containing vitamin K1
CN102552135A (en) Method for preparing vitamin K1 emulsion, and vitamin K1 emulsion
CN1739525A (en) A Novel Polyethylene Glycol Derivatized Phospholipid Encapsulated Nanoparticle Drug Delivery System of Prostaglandin E1
TW202103726A (en) Formulation for oral delivery of proteins, peptides and small molecules with poor permeability
CN1561970A (en) Fat soluble vitamin freeze-drying emulsion and its preparing method
WO2023126026A2 (en) Epa-ee lipid nanocomposite, formulation thereof, preparation method therefor, and application thereof
CN106137957A (en) A kind of oleanolic acid type saponin fat microemulsion and preparation method thereof
CN1973826A (en) Injection containing lipoid microsphere of etoposide and its prepn process
CN1698620A (en) A filter-sterilizable cucurbitacin emulsion and preparation method thereof
CN1827632A (en) Zidovudine palmitate raw material refining method and preparation
CN1562014A (en) V emulsion nicotinate for injection and its preparing method

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20101110

Termination date: 20150527

EXPY Termination of patent right or utility model